Meda makes specialty products, over-the-counter (OTC [non-prescription]) products and branded generics. Meda’s products fall within five therapy areas: respiratory, dermatology, cardiology, pain and inflammation, and central nervous system.

Meda’s board of directors, which has previously rejected offers by both Mylan and Sun Pharma [1], is recommending this latest deal from Mylan to its shareholders. In addition, Meda’s two largest shareholders, both of whom hold around 30% of Meda’s shares, are also reportedly willing to accept the offer, ‘subject to certain conditions’.

The combination of Mylan and Meda will, according to Mylan, ‘create a diversified global pharmaceutical leader with an expansive portfolio of branded and generic medicines and a strong and growing portfolio of over-the-counter (OTC) products’. In fact, according to Mylan CEO, Heather Bresch, Mylan will gain an approximately US$1 billion OTC business once the deal is finalized. She added that the two companies had come to know one another through their successful EpiPen partnership in Europe.

The acquisition of Meda will increase Mylan’s presence in the US and Europe and provides entry into emerging growth markets, including China, Southeast Asia, Russia, the Middle East and Mexico. All of this is complemented by Mylan’s presence in India, Brazil and Africa.

Related article
Mylan launches generic seizure drug in US

Reference
1.  GaBI Online - Generics and Biosimilars Initiative. Sun Pharma looking to buy Sweden’s Meda [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2016 Mar 4]. Available from: www.gabionline.net/Pharma-News/Sun-Pharma-looking-to-buy-Sweden-s-Meda

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.